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disability in the US. OA is due to inflammation and dysfunction of the immune system. One commonly used
therapy for OA is nonsteroidal antiinflammatory drugs (NSAIDs) but they have adverse reactions that affect
the gastrointestinal, renal, and cardiovascular systems. Combination oral enzyme therapy contains naturally
extracted enzymes (bromelain and trypsin) and combines them with the antioxidant rutosid, extracted from
buckwheat or the pagoda tree, as an alternative treatment for OA. The combination oral enzyme therapy has
antiinflammatory, antiedematous, antihistaminic, antiviral, antithrombotic, and fibrinolytic properties. Is this
combination oral enzyme therapy as effective as NSAIDs in the treatment of OA?
Methods: An exhaustive search of available medical literature was conducted through Medline-OVID,
CINAHL, and Web of Science using the keywords: bromelain, nonsteroidal antiinflammatory agents, and
osteoarthritis. Studies were screened for use of the English language and use of randomized controlled trial
design. Relevant articles were assessed for quality using GRADE.
Results: Four studies met inclusion criteria and were included in the systematic review. Four randomized
controlled trials demonstrated that combination oral enzyme therapy was as effective as diclofenac (NSAID)
in management of active osteoarthritis. The studies showed no significant differences when comparing
NSAIDs to combination oral enzyme therapy where regarding pain at rest, pain with movement, Lequesne’s
Functional Index, joint stiffness, range of motion, and swelling in the affected joint.
Conclusion: Combination enzyme therapy has been shown to be as effective as NSAIDs in treatment of
active osteoarthritis. More studies need to be done to evaluate long term efficacy and tolerance. Recommend
use of combination oral enzyme therapy in patients that cannot tolerate NSAIDs or have contraindications to
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Abstract   
 
Background: Osteoarthritis (OA) affects 20 million Americans and OA of the knee is 
the number one disability in the US. OA is due to inflammation and dysfunction of the 
immune system. One commonly used therapy for OA is nonsteroidal antiinflammatory 
drugs (NSAIDs) but they have adverse reactions that affect the gastrointestinal, renal, and 
cardiovascular systems. Combination oral enzyme therapy contains naturally extracted 
enzymes (bromelain and trypsin) and combines them with the antioxidant rutosid, 
extracted from buckwheat or the pagoda tree, as an alternative treatment for OA. The 
combination oral enzyme therapy has antiinflammatory, antiedematous, antihistaminic, 
antiviral, antithrombotic, and fibrinolytic properties. Is this combination oral enzyme 
therapy as effective as NSAIDs in the treatment of OA? 
 
Methods: An exhaustive search of available medical literature was conducted through 
Medline-OVID, CINAHL, and Web of Science using the keywords: bromelain, 
nonsteroidal antiinflammatory agents, and osteoarthritis. Studies were screened for use of 
the English language and use of randomized controlled trial design. Relevant articles 
were assessed for quality using GRADE. 
 
Results: Four studies met inclusion criteria and were included in the systematic review.  
Four randomized controlled trials demonstrated that combination oral enzyme therapy 
was as effective as diclofenac (NSAID) in management of active osteoarthritis. The 
studies showed no significant differences when comparing NSAIDs to combination oral 
enzyme therapy where regarding pain at rest, pain with movement, Lequesne’s 
Functional Index, joint stiffness, range of motion, and swelling in the affected joint.  
 
Conclusion:  Combination enzyme therapy has been shown to be as effective as NSAIDs 
in treatment of active osteoarthritis. More studies need to be done to evaluate long term 
efficacy and tolerance. Recommend use of combination oral enzyme therapy in patients 
that cannot tolerate NSAIDs or have contraindications to NSAID therapy. 
 
Keywords:  Bromelain, nonsteroidal antiinflammatory agents, osteoarthritis 
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Bromelain Containing Enzyme-Rutosid Combination Therapy 
is as Effective as Nonsteroidal Antiinflammatory Agents for 
Treatment of Osteoarthritis 
BACKGROUND 
 Osteoarthritis (OA) is the most common type of joint disease, affecting an 
estimated 27 million individuals in the United States.1 OA is characterized by non-
systemic progressive loss of articular cartilage and bony overgrowth at affected joints. 
These manifestations lead to joint pain, joint stiffness, and disability of varying severity. 
There is an established inflammatory component of OA2,3 and there is increasing 
evidence that immune system dysfunction contributes to the pathophysiology of OA.4-6   
 A first line treatment for active inflammatory OA is nonsteroidal 
antiinflammatory drugs7 (NSAIDs). The primary effect of NSAIDs is to inhibit 
cyclooxygenase enzyme thus inhibiting prostaglandin synthesis, a mediator in the 
inflammatory process. Prolonged or repeated use of NSAIDs has been associated with 
increased risk of gastric and duodenal ulcers resulting in upper gastrointestinal 
perforation and bleeding.8,9 According to the American Gastroenterological Association 
(AGA), each year the side effects of NSAIDs hospitalize over 100 000 people and kill 16 
500 in the US, mostly due to bleeding ulcers.10 A spokesperson for the AGA named 
Byron Cryer, MD. stated, “More than half of all bleeding ulcers are caused by 
NSAIDs.”10 Diclofenac, which was used in each study reviewed in this paper, has been 
shown to be one of the better tolerated NSAIDs.11   
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 Phlogenzym (PE) is an oral enzyme-rutosid combination that combines bromelain 
90mg, trypsin 48mg, and rutosid 100mg. All ingredients are absorbed in the upper 
intestine. Bromelain is a crude extract from pineapple stems and fruit that contains 
various closely related proteases that have demonstrated in vivo antiedematous, 
antiinflammatory, antithrombotic, and fibrinolytic activities.12,13 Bromelain’s 
antiinflammatory properties are from inhibiting the production of bradykinin at the 
inflammatory site via depletion of the plasma kallikrein system.14 Bromelain has been 
associated with diarrhea and stomach and intestinal discomfort.15 Trypsin is a hydrolase 
enzyme secreted by the pancreas and aids in the digestion of food proteins. Trypsin 
enhances fibrinolysis and together with bromelain lowers the proinflammatory cytokines 
including: TNF-α, IL-1, and IFN-γ.16 Rutosid is derived from extraction from the seed of 
the Japanese pagoda tree or buckwheat.17 Rutosid is a phenolic antioxidant which 
accounts for many of its properties, including being antiinflammatory, antihistaminic, and 
antiviral.14  
 The goal of this investigational review is to evaluate another option for the 
treatment of osteoarthritis that has a history of fewer serious side effects than the current 
available treatment with the same efficacy. What is the efficacy of bromelain containing 
enzyme-rutosid combination (ERC) therapy compared to nonsteroidal antiinflammatory 
drugs in the treatment of osteoarthritis?   
METHODS 
 An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, and Web of Science using the keywords: bromelain, 
nonsteroidal antiinflammatory agents, and osteoarthritis. Only English language, 
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randomized controlled trials were included. The bibliographies of each study were further 
searched for relevant sources. The randomized controlled trials were assessed for quality 
using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE) scale.18   
RESULTS 
 The above search strategy of available medical literature yielded eight articles. 
After removing duplicates and irrelevant articles, screening for studies in the English 
language, and including randomized controlled trials four articles remained.16, 19-21 See 
Table 1. 
 
Oral Enzyme Combination Versus Diclofenac in the Treatment of Osteoarthritis of 
the Knee: A Double-Blind Prospective Randomized Study 
 This randomized, double blinded, double dummy, active comparator-controlled 
trial16 compared the effects of Phlogenzym (PE) to diclofenac sodium (DC) for treatment 
of osteoarthritis with a disease flare in one knee joint. The study took place in Pakistan. 
The age of the participants ranged from 36-77 years with 70 female participants and 28 
male participants. The control group was given diclofenac sodium 50 mg, one tablet 
twice daily for 6 weeks whereas the test group was given PE one tablet three times daily 
for 6 weeks. Baseline, 2, 4, and 6 week evaluations were conducted on participants and 
treatment compliance was measured by pill counting at visits. The primary end points 
were Lequesne’s Functional Index (LFI) and complaint index using the visual analog 
scale (VAS) for pain at rest, pain in motion, and restricted function. Secondary endpoints 
included: pain free range of motion and circumference of affected knee measured in 
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centimeters at each evaluation. About half of the participants received physical therapy 
during the study and was equally distributed between the two treatment groups.16 
 Baseline demographics and other baseline characteristics did not reveal relevant 
differences between the two treatment groups. Mean value of LFI decreased by 26.3% in 
the PE group and 23.6% in DC group. Pain at rest revealed a median decrease of 41% for 
PE group and 22.5% for DC group; pain in motion median decrease in both groups of 
28.6%, and joint stiffness decreased by 10% in PE group and 0% in DC group. There was 
no change from baseline in range of motion for either group and joint swelling was 
decreased 1.2% in PE group and no median decrease in the DC group (see Table 2).16 
These values were not statistically different when comparing the two study groups.   
   
 Phlogenzym Versus Diclofenac in the Treatment of Activated Osteoarthritis of the 
Knee: A Double-Blind Prospective Randomized Study 
 This prospective, randomized, double blinded, double dummy phase III clinical 
trial with two parallel groups19 compared the effects of Phlogenzym (PE) to diclofenac  
sodium (DC) for treatment of osteoarthritis with a disease flare in one knee joint. There 
were a total of 63 patients included in the study, 31 in the PE group and 32 in the DC 
group. The control group was given diclofenac sodium 50 mg, one tablet three times 
daily for 1 week and then one tablet twice a day for 2 weeks and the test group was given 
PE one tablet three times daily for 3 weeks. Baseline, 1, 2, 3, and 7 week evaluations 
were conducted on participants and treatment compliance was measured by pill counting 
at visits. The primary end points were Lequesne’s Functional Index (LFI) and complaint 
index using visual analog scale (VAS) for pain at rest, pain in motion, and restricted 
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function. Secondary endpoint was circumference of affected knee measured in 
centimeters at each evaluation.19 
 At the end of therapy (week 3) mean values for relevant end-points had decreased 
as follows: pain at rest 57.6% for the PE group and to 53.9% for the DC group; pain on 
movement 55.6% for PE group and 49.4% for DC group; joint stiffness 52.5% for PE 
group and 52.0% for DC group and LFI scores decreased 29.1% in PE group and 31.5% 
in DC group from baseline scores. At the follow up period (>7 weeks) mean values for 
relevant end-points had decreased as follows: pain at rest 66.7% for PE group and 38.3% 
for DC group; pain with movement 67.4% for PE group and 35.6% for DC group; joint 
stiffness 70.0% for PE group and 45.3% for DC group and LFI scores decreased 36.6% in 
PE group and 19.2% in DC group from baseline (see Table 2).19 
  
Efficacy and Tolerability of Oral Enzyme Therapy as Compared to Diclofenac in 
Active Osteoarthritis of Knee Joint: An Open Randomized Controlled Clinical Trial 
 This randomized, single blinded, active comparator controlled trial20 compared 
the effects of Phlogenzym (PE) to diclofenac sodium (DC) in the treatment of 
osteoarthritis with an active flare of one knee joint. There were 50 participants consisting 
of 31 females and 19 males. The control group was given DC 50mg, one tablet twice a 
day and the test group was given three tablets of PE twice a day for 1 week and then two 
tablets of PE twice a day for 2 weeks. Evaluations were conducted at baseline, 3, and 7 
weeks for follow up. The primary endpoints were pain at rest and pain with movement 
measured subjectively using VAS. Secondary endpoints were joint swelling measured at 
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the upper patella margin at full extension of the knee in centimeters and range of motion 
of the affected knee measured by goniometer at each visit.20   
 According to study, patients were comparable with respect to their presenting 
features; however, there is no data given comparing the demographics of each group at 
the onset of the study. At the end of therapy (3 weeks) the mean scores for the relevant 
end-points had decreased as follows: pain at rest 42.9% in PE group and 25.8% in DC 
group from baseline; pain with motion 39.6% in PE group and 36.3% in DC group from 
baseline and joint swelling 4.5% in PE group and 2.1% in DC group from baseline. At 
the follow up exam (7 weeks from baseline) mean scores for the relevant end-points 
decreased as follows: pain at rest 50.0% in PE group and 32.2% in DC group compared 
to baseline; pain with movement 37.5% in PE group and 41.2% in DC group and joint 
swelling 4.6% for PE group and 1.0% for DC group compared to baseline. There was no 
change in range of motion in either group from baseline recordings (see Table 2). 20 
These values were not statistically different when comparing the two study groups.   
 
Efficacy and Tolerance of an Oral Enzyme Combination in Painful Osteoarthritis of 
the Hip: A Double-Blind, Randomized Study Comparing Oral Enzymes with 
Nonsteroidal Antiinflammatory Drugs 
 This randomized, double blinded, double dummy, active comparator-controlled 
trial21 compared the effects of Phlogenzym (PE) to diclofenac sodium (DC) for treatment 
of osteoarthritis with a disease flare in one hip joint. The study took place in Austria. The 
age of the participants ranged from 35-69 years with 31 female participants and 59 male 
participants. The control group was given diclofenac sodium 50 mg, one tablet twice 
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daily for 6 weeks whereas the test group was given PE two tablets three times daily for 6 
weeks. The first 3 weeks were as an inpatient and last 3 weeks were as outpatient. 
Baseline, 3, and 6 week evaluations were conducted on participants and treatment 
compliance was measured by pill counting at visits. The primary end points were 
Lequesne’s Functional Index (LFI) and Western Ontario and Masters Osteoarthritis Index 
(WOMAC) which measures joint pain, stiffness, and physical function via visual rating 
scale (VRS).21 
 Comparison of baseline demographics and other baseline characteristics of all 
patients included into the study did not reveal relevant differences between the two 
treatment groups. After the 6 weeks observation period the adjusted changes from 
baseline to the end-point of the target parameters were as follows: WOMAC subscale 
pain (PE -10.3 ±1.2 ,DC -9.5 ±1.2); WOMAC joint stiffness (PE -3.9 ±0.5, DC -3.6 ±0.5) 
and LFI (PE -2.89 ±0.47, DC -2.27 ±0.47)(see Table 2).21  
DISCUSSION 
 Bromelain containing enzyme-rutosid combination therapy is as effective 
alternative to NSAIDs in the treatment of active OA. The studies included in the review 
all conclude that combination oral enzyme therapy is as efficacious as NSAIDs in 
primary and secondary end-points of acute flares of OA (see Table 2). In the studies the 
two therapies were equally well tolerated, therefore, safety is likely to be equivalent as 
well. This equivalency is probably due to the lack of sample size in the trials and the 
probability of having a serious adverse reaction threshold was not reached.  
 While the studies16,19-21 demonstrated that combination oral enzymes are effective 
in treatment of OA, they all have limitations. One study,20 the investigators did not blind 
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the patients to the drug that they were receiving. Three of the studies16,19,21 used double 
dummy design to further ensure concealment of study group allocation.  All the studies’ 
primary outcomes agreed with each other and all the studies came to similar conclusions.  
All medication in each trial was provided by the manufacturer of Phlogenzym which 
might have introduced bias. Although precision was not an issue, sample sizes for each 
trial may be of concern in regards to the strength of any recommendations. Furthermore, 
in three of the studies16,19,20 the participants did have a female predominance.  Further 
research, with larger sample sizes and longer treatment regimens to evaluate the efficacy 
of long term enzyme-rutosid combination therapy compared to NSAID therapy in the 
treatment of OA is recommended. In the recommended longer, larger study they could 
also evaluate adverse side effect profiles and measure which therapy is better tolerated 
with less complications.   
 Another consideration is the difference in price of the products. Phlogenzym is 
twice the amount of a diclofenac 50mg pill and three times the amount of an ibuprofen 
400mg pill.22, 23 NSAIDs are available at any pharmacy in the US, whereas, Phlogenzym 
and other bromelain containing enzyme-rutosid combination therapies are only available 
through online ordering.   
CONCLUSION 
 For the management of OA, bromelain containing oral enzyme combination 
therapy has been demonstrated to be as effective as the most commonly used therapy, 
NSAIDs. In some circumstances the enzyme-rutosid combination improved function and 
decreased pain better than diclofenac, but the difference was not statistically significant. 
The overall combined quality of the trials reviewed is moderate quality based on GRADE 
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criteria. An alternative therapy for flares of OA is available and should be considered in 
patients that do not tolerate NSAIDs well or have contraindications to NSAID therapy. It 
should also be considered as an alternative to long term NSAID use for OA. Further 
studies are needed to compare efficacy and tolerance of bromelain containing enzyme-
rutosid combination therapy to NSAIDs in the long term treatment of OA. 
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Table 1. Characteristics of Reviewed Studies 
 
 
a One study20 was single blinded. 
bThree of the studies16,19,20 had a female predominance enrolled. 
cLequesne’s Functional Index- 10 question survey to assess pain, mobility and activities 
of daily living in patients with osteoarthritis 
 
 
Quality Assessment   
 Downgrade Criteria 
Quality Importance No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Pain in affected joint at rest and with movement   
4 
 4 RCTs 
  Serious 
limitationsa 
No serious 
indirectnessb 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Moderate Critical 
Lequesne’s Functional Index c(LFI)   
3 3 RCT No serious limitations 
No serious 
indirectnessb 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely High Critical 
Stiffness of affected joint   
3 3 RCT No serious limitations 
No serious 
indirectnessb 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely High Important 
Range of motion of affected joint   
2 2 RCT  
Serious 
limitationsa 
No serious 
indirectnessb 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Moderate Important 
Swelling of affected joint   
3 3 RCT Serious limitationsa 
No serious 
indirectnessb 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Moderate 
Less 
 important 
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Table 2. Summary of Findings 
a Statistical significance of difference between the two study groups19. All other values were not statistically significantly different (P-
value >0.05).16,20,21 
 Number of Patients Outcomes 
Study Duration of study Phlogenzym (PE) group (total) 
Diclofenac 
(DC) 
group (total) 
Pain in affected joint 
(mean % decrease) 
Lequesne’s Functional Index 
(Mean % decrease) 
Stiffness in affected joint 
(Mean % increase) Range of Motion in      
affected joint 
Swelling of 
affected joint 
(Mean % 
decrease) 
PE DC PE DC PE DC PE DC 
Akhtar et al16 6 weeks 46 52 
At rest 
41.0 
At rest 
22.5 
26.3 23.6 10 0.0 No change from baseline 1.2 0.0 In motion 
28.6 
In motion 
28.6 
Singer et al19 
3 weeks (end of therapy) 
 
31 32 
At rest 
57.6 
At rest  
53.9 29.1 31.5 52.5 52.0 
------- 
No change from 
baseline for both 
groups 
In motion 
55.6 
In motion 
49.4 
7 weeks (follow-up) 
At rest 
66.7 
At rest  
38.3 36.6 19.2a 70.0 45.3 In motion 
67.4 
In motion 
35.6a 
Tilwe et al20 
3 weeks (end of therapy) 
25 25 
At rest 
42.9 
At rest  
25.8 
------- ------- ------- ------- No change from baseline 
4.5 2.1 In motion 
39.6 
In motion 
36.3 
7 weeks (follow up) 
At rest 
50.0 
At rest  
32.2 4.6 1.0 In motion 
37.5 
In motion 
41.2 
Klein et al21 6 weeks 45 45 
Pain in affected joint 
(mean adjusted difference 
PE/DC ±SD) 
Lequesne’s Functional Index 
(mean adjusted difference 
PE/DC ±SD) 
Joint stiffness (Mean 
adjusted difference PE/DC 
±SD)   
PE DC PE DC PE DC 
-10.3(±1.2) -9.5(±1.2) -2.89(±0.47 -2.27(±0.47) -3.9(±0.5) -3.6(±0.5) ------- ------- 
